Bing Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bing Liu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
A.H. Jan Danser
Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam University, Rotterdam, Netherlands
1 shared publication- Chengzhou Mao
Department of Anatomy and Histology, Shenzhen University Medical School, Shenzhen, China
1 shared publication - Fu-Sheng Wang
Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China
1 shared publication - Letong Cai
Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China
1 shared publication Li Yu
Department of Hematology and Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China
1 shared publication- Li-Zhong Liu
Faculty of Medicine, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011657
Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8 + T cells
Background: Tumor-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) facilitates tumor progression, but the role of immune cell-intrinsic PCSK9 in tumor control remains unclear. Methods: Orthotopic models of pancreatic cancer and melanoma in Pcsk9 -deficient mice were established and tumor-infiltrating immune cells were analyzed using single-cell RNA sequencing and flow cytometry. The effect of genetic disruptions of PCSK9 on murine CD8 + T cells and human chimeric antigen receptor (CAR)-T cells was evaluated both in vitro and in vivo. Results: Ablation of host Pcsk9 remarkably suppressed tumor growth and prolonged the survival of tumor-bearing mice, while tumor cells still express PCSK9. The enhanced tumor suppression in Pcsk9 -deficient mice depended on CD8 + T cells. Notably, PCSK9 expression was induced in CD8 + tumor-infiltrating lymphocytes (TILs). Consequently, Pcsk9 ablation potentiated the antitumor capacity of CD8 + T cells, showing increased intratumoral infiltration and improved cytotoxic function, along with higher proportions of both effector-memory precursor exhausted (T PEX ) and terminally exhausted (T TEX ) CD8 + TILs. Additionally, disruption of PCSK9 in both murine CD8 + T cells and human CAR-T cells, synergistic with PD-1 blockade, promoted tumor suppression. Conclusion: These findings indicate that PCSK9 inhibits the antitumor function of CD8 + T cells, suggesting it may be a promising target for enhancing T-cell-based cancer immunotherapy.
- 15 July 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011657
Open AccessDisruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8 + T cells
Background: Tumor-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) facilitates tumor progression, but the role of immune cell-intrinsic PCSK9 in tumor control remains unclear. Methods: Orthotopic models of pancreatic cancer and melanoma in Pcsk9 -deficient mice were established and tumor-infiltrating immune cells were analyzed using single-cell RNA sequencing and flow cytometry. The effect of genetic disruptions of PCSK9 on murine CD8 + T cells and human chimeric antigen receptor (CAR)-T cells was evaluated both in vitro and in vivo. Results: Ablation of host Pcsk9 remarkably suppressed tumor growth and prolonged the survival of tumor-bearing mice, while tumor cells still express PCSK9. The enhanced tumor suppression in Pcsk9 -deficient mice depended on CD8 + T cells. Notably, PCSK9 expression was induced in CD8 + tumor-infiltrating lymphocytes (TILs). Consequently, Pcsk9 ablation potentiated the antitumor capacity of CD8 + T cells, showing increased intratumoral infiltration and improved cytotoxic function, along with higher proportions of both effector-memory precursor exhausted (T PEX ) and terminally exhausted (T TEX ) CD8 + TILs. Additionally, disruption of PCSK9 in both murine CD8 + T cells and human CAR-T cells, synergistic with PD-1 blockade, promoted tumor suppression. Conclusion: These findings indicate that PCSK9 inhibits the antitumor function of CD8 + T cells, suggesting it may be a promising target for enhancing T-cell-based cancer immunotherapy.